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DNA methylation map in circulating 
leukocytes mirrors subcutaneous 
adipose tissue methylation pattern: 
a genome-wide analysis from non-
obese and obese patients
A. B. Crujeiras1,2,3,*, A. Diaz-Lagares1,*, J. Sandoval4, F. I. Milagro3,5, S. Navas-Carretero3,5, 
M. C. Carreira2,3, A. Gomez1, D. Hervas6, M. P. Monteiro7, F. F. Casanueva2,3, M. Esteller1,8,9 & 
J. A. Martinez3,5
The characterization of the epigenetic changes within the obesity-related adipose tissue will provide 
new insights to understand this metabolic disorder, but adipose tissue is not easy to sample in 
population-based studies. We aimed to evaluate the capacity of circulating leukocytes to reflect 
the adipose tissue-specific DNA methylation status of obesity susceptibility. DNA samples isolated 
from subcutaneous adipose tissue and circulating leukocytes were hybridized in the Infinium 
HumanMethylation 450 BeadChip. Data were compared between samples from obese (n = 45) and 
non-obese (n = 8–10) patients by Wilcoxon-rank test, unadjusted for cell type distributions. A global 
hypomethylation of the differentially methylated CpG sites (DMCpGs) was observed in the obese 
subcutaneous adipose tissue and leukocytes. The overlap analysis yielded a number of genes mapped 
by the common DMCpGs that were identified to reflect the obesity state in the leukocytes. Specifically, 
the methylation levels of FGFRL1, NCAPH2, PNKD and SMAD3 exhibited excellent and statistically 
significant efficiencies in the discrimination of obesity from non-obesity status (AUC > 0.80; p < 0.05) 
and a great correlation between both tissues. Therefore, the current study provided new and valuable 
DNA methylation biomarkers of obesity-related adipose tissue pathogenesis through peripheral blood 
analysis, an easily accessible and minimally invasive biological material instead of adipose tissue.
The prevalence of obesity and its associated disorders is increasing extremely rapidly worldwide and they are 
currently considered to be pandemic non-communicable diseases and a major challenge for the healthcare sys-
tem1,2. Many metabolic alterations, such as obesity, are due to the interplay between environmental, lifestyle and 
genetic factors3. It is well known that physical inactivity and unhealthy dietary patterns exert major influences 
on metabolic syndrome, diabetes and obesity4. However, despite intensive genetic research into these alterations, 
the basic mechanisms and pathogenesis of obesity are still poorly understood. In this regard, emerging evidence 
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suggests that epigenetics represents one link between environmental factors and the greater predisposition to 
develop obesity and its associated comorbidities5–8.
Epigenetic markers might explain the link between lifestyle and the risk of disease and have been proposed to 
be sensitive biomarkers and potential therapeutic targets for disease management that could contribute to per-
sonalized medicine9. The epigenetic machinery involves several levels of regulation, such as DNA methylation, 
post-translational histone modifications, nucleosome positioning and non-coding RNAs10. Among the epigenetic 
mechanisms, DNA methylation is the best-known epigenetic marker and has been proposed as a new generation 
of biomarkers with great diagnostic and prognostic promise for clinicians10. Regarding obesity susceptibility, 
several studies have investigated methylation sites in or near known candidate genes and provided evidences 
that obesity is associated with altered epigenetic regulation of a number of metabolically important genes5,11,12. 
Moreover, with the recent development of genome-wide methods for quantifying site-specific DNA methylation, 
studies investigating associations across a large number of genes and CpGs are being conducted with leuko-
cytes or adipose tissue5,11,12. These approaches identified obesity-associated differentially methylated sites that are 
enriched in obesity candidate genes and in other genes with a wide diversity of other functions or even unknown 
properties related to obesity or adipose tissue biology5,13,14.
Epigenetic changes may be more tissue specific, and obesity pathophysiology is strongly associated with 
changes in the physiological functions of adipose tissue that lead to adipose tissue dysregulation15. This fact rep-
resents a huge challenge to the search for obesity-associated epigenetic biomarkers for the diagnosis and manage-
ment of the disease as adipose tissue is inaccessible without surgery. In lieu of adipose tissue, epigenetic markers 
might be detectable in easily accessible samples, such as peripheral blood. In the obesity field, a very recently 
published study provided evidence of an inverse correlation between the DNA methylation of HIF3A in blood 
leukocytes and its expression in adipose tissue, which suggests that whole blood can be used to identify robust 
and biologically relevant epigenetic variation related to BMI14. Additionally, it has further been demonstrated 
in a genome-wide DNA methylation study of monozygotic twins discordant for obesity and liver fat that blood 
epigenetic profiling has great potential for better characterizing the obesity phenotype and identifying subjects 
who are most at risk for developing metabolic complications16. A recent, large, prospective, case-control study 
demonstrated that differences in DNA methylation in peripheral blood predict future type 2 diabetes incidence17. 
Leukocytes were also engaged to evaluate the DNA methylation of the displacement loop region of mitochondrial 
genome in obesity and was associated with insulin resistance18. Moreover, the influence of physical activity19, 
dietary factors20, gender and race/ethnicity21 on the DNA methylation of peripheral blood cells has been demon-
strated. Additionally, it has been demonstrated that responses to weight loss treatment can be influenced and 
predicted by the DNA methylation status of leukocytes prior to treatment22,23.
The aim of the current study was to evaluate the capacity of circulating leukocytes to reflect the DNA methyla-
tion status of adipose tissue in an attempt to provide better insight in adipose tissue-specific epigenetic signatures 
of obesity susceptibility in easily accessible samples, such as peripheral blood instead of adipose tissue.
Results
Global pattern of subcutaneous adipose tissue DNA methylation in obese and non-obese 
subjects. We performed a genome-wide DNA methylation analysis to characterize the global methylation 
status in obesity. We found that the average global levels subcutaneous adipose tissue DNA methylation (Fig. 1a) 
were similar between the obese and non-obese subjects. When subsequent analyses were performed to compare 
each of the CpG sites individually, 12,043 CpG sites were found to be significantly differentially methylated in 
the subcutaneous adipose tissue of obese compared with non-obese subjects based on the application of a false 
discovery rate (FDR) of < 0.05 and a difference between groups of delta β ≥ 10% (see Supplementary Table S3). 
A quantile-quantile (QQ) plot representing the expected and observed p-values (lambda value = 3.9) is shown in 
Supplementary Figure S1a.
Among the differentially methylated CpGs (DMCpGs), the obese subcutaneous adipose tissue exhibited lower 
methylation levels than the non-obese subcutaneous adipose tissue (Fig. 1b). The highest CpG frequencies in the 
obese samples were in the range of 0.40 to 0.60 (β -values), whereas the non-obese samples exhibited β -values 
greater than 0.60. These results suggest that adipose tissue from obese patients is characterized by a greater hypo-
methylation level. The identified CpG sites corresponded to 4,481 unique genes and they were able to separate 
both groups of samples using a hierarchical cluster approach (Fig. 1c). Compared across all analyzed sites in the 
Infinium HumanMethylation450 BeadChip, the DMCpGs of the subcutaneous adipose tissue in obese patients 
respect to non-obese subjects were underrepresented in the TSS200 and 1st exon and overrepresented in the 
body and intergenic regions (Fig. 2a). Regarding the CpG context, the DMCpGs were overrepresented in shelf, 
shore and open sea positions, whereas a statistically significant underrepresentation was observed in CpG island 
regions (Fig. 2b). Moreover, the distribution of the DMCpGs were primarily found on chromosomes 1, 2, 12 and 
19 compared with all analyzed sites (Fig. 2c). Noteworthy, a gene ontology (GO) analysis showed that the identi-
fied obesity-related CpGs (4,481 genes) were enriched in biological functions related to the adipose tissue, such 
as cell adhesion and differentiation, immune response, transport, inflammatory responses, metabolic processes 
and response to hypoxia (Fig. 2d).
Mirroring the subcutaneous adipose tissue DNA methylation map in leukocytes from obese 
and non-obese subjects. Like in adipose tissue, the global DNA methylation levels in the leukocytes were 
similar between the non-obese and obese patients (Fig. 3a). When the CpGs were analyzed individually, 4,815 
CpGs were found to be differentially methylated in the obese patients compared with the non-obese patients 
based on the application of a false discovery rate (FDR) of < 0.05 and a difference between groups of delta β > 5% 
(Fig. 3b and see Supplementary Table S4). A quantile-quantile (QQ) plot representing the expected and observed 
p-values (lambda value = 3.2) is shown in Supplementary Figure S1b.
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Although a lower percentage of DMCpGs was observed in the leukocytes than in the subcutaneous adipose 
tissue, the direction of the overall methylation was similar with a higher percentage of methylation lost in both 
tissues from the obese patients (Fig. 3b) and the identified DMCpGs were able to separate both groups of samples 
using a hierarchical cluster approach (Fig. 3c). Next, to identify the CpGs in leukocytes that were able to reflect 
the obesity state of the adipose tissue, a Venn diagram was created using the DMCpGs that were identified in the 
adipose tissue and leukocytes. This analysis yielded 176 common CpGs from which 78 CpGs that represented 
68 unique genes exhibited the same methylation direction in both tissues. Among these CpGs, 13 exhibited high 
methylation levels, and 66 exhibited low methylation levels in the obese patients relative to the non-obese patients 
(Fig. 4A and Supplementary Table S5). Indeed, the 78 common CpGs exhibited globally lower methylation levels 
in the obese adipose tissue and leukocytes compared with the non-obese samples (Fig. 4B). A GO analysis was 
performed to test whether some molecular functions and biological processes were significantly associated with 
the 68 common genes that exhibited differences in DNA methylation status between both groups. Among the 
significantly enriched biological processes, the top overrepresented categories were immune response, cell migra-
tion, cell adhesion, response to hypoxia, cell cycle arrest and transdifferentiation (Fig. 4C).
In order to assess the biological relevance, the CpG sites representing promoter regions (TSS1500, TSS200, 5′ 
UTR and 1st exon) in the islands and shores were selected. Table 1 reports the 23 CpG sites with greatest differ-
ences between the obese and non-obese patients in both the adipose tissue and leukocytes ranked by gene name. 
Among these genes, FGFRL1, LMF2, NCAPHR, PODXL, PIP5K1A, PNKD, PTPRCAP, RSRC2, KNTC1, SMAD3 
and WDR45L (corresponding to 9 CpG sites) were identified as genes that potentially reflect the obesity state in 
the leukocytes because they exhibited differences of similar magnitude (differences greater than 5%) in terms 
of the β -values (Table 2). Gender does not exhibited statistically significant influence to the methylation levels 
of the studied genes and the association between the methylation levels of the identified genes was maintained 
when BMI was included as continuous variable adjusted for gender (data not shown). Moreover, after literature 
search, these identified genes containing obesity-related DMCpGs were apparently involved in important process 
associated with adipose tissue homeostasis, such as cell proliferation and differentiation, senescence, network of 
inflammation, cell-cell adhesion and mitochondrial function as has been previously reported (Table 2).
Because DNA methylation affect transcription, the mRNA expression of the identified genes was exam-
ined, based on reported subcutaneous adipose tissue gene expression differences between obese and non-obese 
patients24. Relevantly, an inverse correlation was observed between methylation and gene expression of 6 genes: 
PNKD, PODXL, PTPRCAP, SMAD3 and WDR45L as well as a trend for statistical correlation in FGFRL1 
(Table 2). Moreover, we found correlations between BMI and the β -values of the CpGs in the subcutaneous 
adipose tissue mapped to, PNKD (cg22712983; r = 0.35; p = 0.014), PODXL (cg02051077; r = − 0.33; p = 0.021), 
PTPRCAP (cg02874905; r = − 0.36; p = 0.011), and SMAD3 (cg07576222; r = − 0.28; p = 0.049). Additionally, 
Figure 1. Profile of DNA methylation according to obesity state in adipose tissue. Differences in the 
global methylation levels of the overall valid CpGs between the obese and non-obese subcutaneous adipose 
tissue samples (a). Global differences in the methylation levels of the 12,043 differentially methylated CpGs 
(DMCpGs) identified by 450-k array analysis (b). Supervised clustering of the 12,043 CpGs that were found 
to be differentially methylated between the obese and non-obese groups (c). P-values were computed using 
wilcoxon rank sum test.
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FGFRL1 (cg25932599; r = − 0.27; p = 0.059) and PIPK1A (cg06936779; r = − 0.26; p = 0.067) showed a trend for 
statistical correlation with BMI.
To further analyze the diagnostic power of the identified DMCpGs, receiver operating characteristic (ROC) 
curves were performed (Fig. 5). Relevantly, the areas under the ROC curves (AUCs) for FGFRL1, NCAPH2, 
PNKD, and SMAD3 evidenced excellent and statistically significant efficiencies in discriminating obesity from 
non-obesity in both the subcutaneous adipose tissue (Fig. 5a) and leukocytes (Fig. 5b). Moreover, we found a 
great correlation in the DNA methylation between the subcutaneous adipose tissue and leukocytes for FGFRL1 
(r = 0.77; p < 0.001), NCAPH2 (r = 0.68; p < 0.001), PODXL (r = 0.70; p < 0.001) and SMAD3 (r = 0.74; 
p < 0.001).
Discussion
The characterization of the epigenetic changes associated with obesity will provide new insights about the patho-
physiological processes that are involved in this metabolic disorder and help us to develop better approaches 
for prevention and disease management, useful biomarkers and treatment strategies. In the current work, we 
used Illumina HumanMethylation 450k arrays to characterize the genome-wide DNA methylation profile associ-
ated with obesity in adipose tissue and to identify the CpG sites in circulating leukocytes that were differentially 
methylated relative to adipose tissue. The overlap analysis sought to identify DNA methylation markers that can 
be detected in an easily accessible biological source, i.e., blood, yielded 78 differentially methylated CpGs that 
exhibited changes in the same directions in the adipose tissue and the leukocytes. These 78 CpGs anoted to 68 
unique genes. Nine of these 78 CpGs were located in promoters and islands and they mapped to 11 unique genes 
(FGFRL1, LMF2, NCAPHR, PODXL, PIP5K1A, PNKD, PTPRCAP, RSRC2, KNTC1, SMAD3 and WDR45L) 
which were identified as potential target genes that could reflect the obesity state in leukocytes because they 
exhibited the greatest differences between the obese and non-obese samples. These genes were involved in impor-
tant processes associated with adipose tissue homeostasis, such as cell proliferation and differentiation, senes-
cence, the network of inflammation, cell-cell adhesion and mitochondrial function. Moreover, the expression 
of FGFRL1, PNKD, PODXL, PTPRCAP, SMAD3 and WDR45L based on previously reported data correlated 
inversely with the methylation levels in the subcutaneous adipose tissue suggesting a potential epigenetic regula-
tion associated to obesity.
Strong evidence that complex diseases, such as metabolic disorders, are under the influence of epigenetic 
modifications even in early life is opening up exciting new avenues for the identification of DNA methylation 
biomarkers associated with these disorders and the estimation of future disease risk25. Biomarkers are naturally 
Figure 2. Characteristics of the candidate differentially methylated CpGs (DMCpGs). Genomic 
distributions of the differentially methylated CpG sites and their respective locations regarding the broader CpG 
context (a), the gene region (b) and chromosome distribution (c). Summary of the gene ontology (GO) analysis 
of the biological process categories for the 4,481 genes represented by the 12,043 differentially methylated CpG 
sites (d). *Significant differences (p < 0.05) in the distributions of differentially methylated CpG sites compared 
with all analyzed sites on the Infinium HumanMethylation450 BeadChip, by chi-square test.
www.nature.com/scientificreports/
5Scientific RepoRts | 7:41903 | DOI: 10.1038/srep41903
occurring characteristics from which particular pathological processes or diseases can be identified or monitored. 
Biomarkers reflect past environmental exposures, predict disease onset and course and determine a patient’s 
response to therapy. Epigenetic changes represent these characteristics, and the majority of epigenetic biomarkers 
that have been discovered to date are based on the epigenetic marker of DNA methylation. DNA methylation 
biomarkers with diagnostic, prognostic and predictive powers are already in clinical trials and are used in clinical 
settings for some diseases such as cancer26.
Regarding obesity susceptibility, studies have investigated methylation sites in or near known candidate 
genes and across a large number of genes and CpGs with genome-wide methods. These approaches identify 
obesity-associated differentially methylated sites that are enriched in obesity candidate genes and in genes with 
a wide diversity of other functions or even unknown properties related to obesity or adipose tissue functions5,11. 
Thus, specific patterns of DNA methylation have been found to be associated with obesity itself14,27,28, with 
BMI14,29 and with responses to obesity therapy22,23,30–32 in specific candidate gene and genome-wide DNA meth-
ylation analyses in leukocytes and/or adipose tissue. Recently, the methylome of isolated human fat cells from 
post-obese and BMI-matched never-obese women was also characterized, and a number of adipogenesis and 
lipid metabolism genes have been identified as epigenetically regulated33,34.
Because blood is easily accessible and is routinely sampled in clinical and large-scale studies, peripheral blood 
cells are the most frequently used source of DNA for epigenetic studies. However, epigenetic changes may be 
more tissue-specific, and the blood cell methylation profile may not necessarily reflect the epigenetic states in 
other tissues. Currently, a massive effort is directed at providing better insight into tissue-specific epigenetic 
signatures and their roles in disease development. In this regard, very recently, Rönn et al.29 demonstrated that 
epigenetic biomarkers in blood can mirror age-related epigenetic signatures in biologically relevant target tissues 
such as adipose tissue. Moreover, Dick and colleagues14 described the first systematic analysis of the association 
between variation in DNA methylation and body mass index. That work reported an inverse correlation between 
DNA methylation and HIF3A expression in adipose tissue and drew attention to the potential functional rel-
evance of epigenetic variation at the identified locus. Relevantly, the DNA methylation profile of HIF3A was 
reflected in whole blood, which suggests that the assessment of DNA methylation in whole blood can identify 
robust and biologically relevant epigenetic variation that is related to BMI14. In the current research, we were 
unable to detect differences in methylation levels of HIF3A in subcutaneous adipose tissue nor in leukocytes, 
probably because differences in the study design, sample size, the threshold used for selection of candidates and 
even the location of subcutaneous adipose tissue sampling. However the current study adds new information to 
this issue. By comprehensively interrogating 485,000 CpG sites in samples of subcutaneous adipose tissue 12,043 
Figure 3. Profile of DNA methylation depending on obesity state in leukocytes. Differences in the global 
methylation levels of the overall valid CpGs between the obese and non-obese leukocyte samples (a). Global 
differences in the methylation levels of the 4,815 differentially methylated CpGs identified by 450-k array 
analysis (b). Supervised clustering of the 4815 CpGs that were found to be differentially methylated between the 
obese and non-obese group (c). P-values were computed using wilcoxon rank sum test.
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CpG sites annoted to 4,481 unique genes were found to be differentially methylated between obese and non-obese 
samples. Among the genes associated to these DMCpGs, 12 genes (CHT11, ZBTB16, MAD1L1, E2F5, FGFRL1, 
CCDC92, ACSF3, MAML3, ASAP2, EHBP1L1, RBPMS, TBC1D16) were also observed in a previous study that 
compares subcutaneous adipose tissue of BMI-discordant monozygotic twin pairs, even though not in the same 
CpG loci for some of them28. PLEC1 and ITIH5 were also found to be inversely associated with obesity state in 
our study, similar to that reported by Rönn et al.29. Moreover, among the genes mapped by the DMCpGs revealed 
in the subcutaneous adipose tissue we found a significant number of defined obesity genes that were previously 
demonstrated to undergo DNA methylation changes after gastric bypass and weight loss31. As examples of these 
common genes were FTO, LEPR, PHACTR1, SLC22A8, NDUFS2, NCOR2, PRDM16 several homeobox genes 
(HOXA3, HOXC4, HOXD3, HOXD4, HOXB6, MSX1, EMX2OS, EMX2) and genes involved in epigenome reg-
ulation (HDAC4, HDAC3, HDAC9, DNMT3A).
Strikingly, by means of a stringent filtering we were able to identify an obesity-related epigenetic signature 
of adipose tissue in a biological source that is easily accessible, i.e., blood leukocytes. The identified epigenetic 
signature could be relevant to the personalized management of obesity because most of the associated genes 
are involved in pathways associated with adipose tissue function. Thus, the most overrepresented pathways of 
differential methylated CpG sites were related to the structural components of the cellular matrix, inflammation 
and adipogenesis. Among the identified differentially methylated genes, fibroblast growth factor receptor-like 1 
(FGFRL1) has been postulated to be involved in metabolism signalling and insulin processing35 and it is an early 
indicator of adipogenesis36. Moreover, FGFRL1 exerts a negative effect on cell proliferation and a positive effect 
on cell differentiation37 and is involved in tumor growth38. Noteworthy, the body of this gene was found to be 
hypermethylated in the subcutaneous adipose tissue of BMI-discordant monozygotic twin pairs28. By contrast in 
the current study low methylation levels of its promoter and island was found in the obese patients, similar to pre-
vious report29. The condensin II gene NCAPH2 is a recently discovered gene that has been found to be involved in 
senescence39, which is a process that is increased in dysfunctional obese adipose tissue and is related to the devel-
opment of metabolic disturbances40. The most relevant differentially methylated gene identified was SMAD family 
member 3 (SMAD3). This gene is a TGF-beta effector protein and is a miscellaneous factor of adipogenesis. The 
loss of SMAD3 results in the transformation of white adipose tissue (WAT) to a brown adipose tissue (BAT)-like/
beige cell phenotype and thus increases basal energy expenditure and protects against high-fat diet-induced 
obesity and type 2 diabetes mellitus41. Therefore, the blockage of SMDA3 protects against obesity and type 
2 diabetes mellitus41. The WAT of SMAD3−/− mice exhibits decreased adiposity, and these mice also exhibit 
Figure 4. Comparison of the differential methylation profiles associated with obesity between the adipose 
tissue and leukocyte samples. A Venn diagram was created to obtain the common differentially methylated 
CpGs (DMCpGs) (A). Global differences in the methylation levels of the 78 common differentially methylated 
CpGs identified by the 450-k array analysis (B). Summary of the gene ontology (GO) analysis of the biological 
process categories for the differentially methylated genes represented by the CpG sites located in the promoter 
regions and islands (C). P-values were computed using wilcoxon rank sum test.
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increased whole-body glucose uptake and insulin sensitivity and decreased expression of genes involved in fatty 
acid storage42. This effect is probably attributable to the modulation of WAT metabolism, which increases mito-
chondrial biogenesis. Regarding mitochondrial function, mutations of the identified paroxysmal nonkinesigenic 
dyskinesia (PNKD) gene are involved in the development of a disease induced by mitochondrial dysfunction43. 
Although there is currently no evidence regarding the involvement of this gene in adipose tissue function or the 
pathogenesis of obesity, the increased methylation levels observed in the adipose tissue and leukocytes of the 
obese patients compared with the non-obese patients in the current work suggest that this gene should be further 
functionally explored in terms of its role in the pathogenesis of the obese adipose tissue.
The strength and novelty of the current work are represented in the paired analyses of the adipose tissues and 
circulating leukocytes from the same patients. These analyses allowed us to select an epigenetic signature of the 
obesity-related adipose tissue phenotype with high accuracy based on a non-invasive and easy accessible source 
of DNA. The difference in sample size and age between the non-obese and obese patients could be a limitation of 
this study because the effects of age on obesity-related epigenetic markers need to be further determined. In fact, 
the association between age and the DNA methylation profile was previously reported29,44. Moreover, as several 
technical factors and environmental exposures are thought to cause aberrant DNA methylation, the effect of die-
tary factors and smoking, as well as the tissue heterogeneity and cell type, among others should also be taken into 
consideration in the differential methylation analysis by performing a multi-variate analysis. In the current study 
the Wilcoxon rank test was performed for the analysis instead of using linear regression models because the sam-
ple size to gain robustness. Moreover, the results were focused only in those CpG sites with a methylation pattern 
in leukocytes similar to that observed in adipose tissue and located in promoter and islands/shores regions. This 
further filtering out was performed in order to minimize the impossibility of controlling for potential confounder 
factors. The absolute differences in DNA methylation between the obese and non-obese patients were small in 
both the subcutaneous adipose tissue and the leukocytes, although these differences could have functional signif-
icances similar to those previously reported for human adipose tissue45–48, isolated fat cells33,34 and human skeletal 
muscle49,50. Despite these facts, the data obtained in the current study provide new and valuable DNA methylation 
TargetID CHR Position Gene name Gene region CpG context
Differences adipose 
tissue (Ob-Nob)
Differences 
leukocytes 
(Ob-Nob)
cg02379560 4 40859280 APBB2;APBB2;APBB2;APBB2; APBB2;APBB2;APBB2
Body;TSS200;TSS200;Body;TSS200; 
Body;TSS200 S_Shore − 0.11 − 0.07
cg20251225 1 1609551 CDK11B;CDK11B;CDK11B;CDK11B;CDK11B;LOC728661;CDK11B
Body;Body;Body;Body; 
Body;5′ UTR;5′ UTR S_Shore − 0.10 − 0.06
cg15681239 3 38080203 DLEC1;DLEC1 TSS1500;TSS1500 N_Shore − 0.11 − 0.06
cg25932599 4 1005201 FGFRL1;FGFRL1;FGFRL1 TSS1500;TSS1500; TSS1500 Island − 0.12 − 0.11
cg15644324 1 42384647 HIVEP3;HIVEP3 TSS200;TSS200 S_Shore 0.13 0.07
cg00514575 5 180231155 MGAT1;MGAT1;MGAT1; MGAT1;MGAT1
TSS1500;5′ UTR;TSS1500; 
5′ UTR;TSS1500 S_Shore − 0.12 − 0.06
cg11201447 8 128808063 MIR1204;PVT1 TSS200;Body S_Shore − 0.10 − 0.06
cg25152348 22 50946712 NCAPH2;LMF2;NCAPH2; NCAPH2;NCAPH2
1stExon;TSS1500;5′ UTR; 
5′ UTR;1stExon Island − 0.10 − 0.13
cg06936779 1 151171405
PIP5K1A;PIP5K1A;PIP5K1A; 
PIP5K1A;PIP5K1A;PIP5K1A; 
PIP5K1A;PIP5K1A
5′ UTR;1stExon;5′ UTR; 
1stExon;5′ UTR;1stExon; 
1stExon;5′ UTR
Island − 0.12 − 0.09
cg18437077 7 100860918 PLOD3;PLOD3;ZNHIT1 1stExon;5′ UTR;TSS200 Island − 0.11 − 0.06
cg22712983 2 219187374 PNKD;PNKD TSS1500;Body N_Shore 0.12 0.10
cg02051077 7 131241343 PODXL;PODXL; PODXL;PODXL 5′ UTR;1stExon;5′ UTR;1stExon Island − 0.11 − 0.07
cg11381564 6 32808619 PSMB8;PSMB8 3′ UTR;3′ UTR S_Shore − 0.14 − 0.08
cg14010720 20 62168878 PTK6 TSS200 S_Shore − 0.13 − 0.06
cg10542975 11 67205096 PTPRCAP;PTPRCAP 5′ UTR;1stExon S_Shore − 0.15 − 0.06
cg02874908 11 67205113 PTPRCAP;PTPRCAP 5′ UTR;1stExon S_Shore − 0.12 − 0.09
cg17858911 12 123012351 RSRC2;RSRC2; RSRC2;KNTC1
TSS1500;TSS1500; 
TSS1500;5′ UTR S_Shore − 0.12 − 0.11
cg02996471 19 3178512 S1PR4 TSS1500 N_Shore − 0.12 − 0.06
cg07496545 5 140683737 SLC25A2 TSS200 Island 0.12 0.05
cg07576222 15 67357975 SMAD3 TSS1500 Island − 0.11 − 0.07
cg13104938 11 843956
TSPAN4;TSPAN4;TSPAN4; 
TSPAN4;TSPAN4;POLR2L; 
TSPAN4;TSPAN4
TSS1500;5′ UTR;TSS200;5′ UTR; 
5′ UTR;TSS1500;5′ UTR;5′ UTR S_Shore 0.11 0.06
cg23713156 17 80606235 WDR45L;WDR45L 5′ UTR;1stExon Island − 0.10 − 0.09
Table 1.  The twenty-three highest commonly differentially methylated CpGs in subcutaneous adipose tissue 
and leukocytes between obese (Ob) and non-obese (Nob) located in promoter and island and shore and sorted 
by gene name.
www.nature.com/scientificreports/
8Scientific RepoRts | 7:41903 | DOI: 10.1038/srep41903
biomarkers together with other previously reported data in adipose tissue. The proposed epigenetic biomarkers 
in the current study could help to elucidate the molecular mechanisms involved in adipose tissue pathogenesis 
associated with obesity that can be examined in an easily accessible biological material, i.e., blood. During the 
peer-review process of the current work, an independent study evaluating epigenome-wide profiling of DNA 
methylation in paired samples of adipose tissue and blood suggested that the magnitude of within-subject corre-
lation between blood and adipose tissue does not guarantee the utility of surrogate epigenetic markers because the 
association is phenotype-specific51. Relevantly, the current work reports a number of CpG sites that has a similar 
pattern of methylation levels in both adipose tissue and leukocytes and both are associated with an obesity state.
Further prospective studies are needed to corroborate the suitability of the proposed obesity-related epigenetic 
signature in leukocytes for clinical applications that improve obesity understanding and management taking into 
account the tissue heterogeneity and cell type as well as the environmental factors that influence the DNA meth-
ylation pattern. In conclusion, the current results provide evidence that the blood DNA methylation profile has 
great potential for better characterizing the obesity phenotype and improving the early diagnosis of and effective 
personalized therapies for this metabolic disorder.
Subjects and Methods
Study participants. The DNA methylation statuses of a total of 108 DNA samples that were hybridized in 
the Infinium HumanMethylation 450 BeadChip were evaluated (see Supplementary table S1). A portion of these 
DNA samples were isolated from paired abdominal, periumbilical subcutaneous adipose tissue and leukocytes 
from 45 obese patients (n = 23 women and n = 22 men). Alternative DNA samples from non-obese patients were 
obtained from abdominal, periumbilical subcutaneous adipose tissue (n = 8; 4 women and 4 men) and from 
leukocytes (n = 10; 5 men and 5 women). The range of ages and BMIs of the obese patients were 20 to 83 years 
and 26.2 to 53.1 kg/m2, respectively. The ranges of ages and BMIs of the non-obese patients were 23 to 79 years 
and 20.1 to 24.3 kg/m2, respectively (see Supplementary table S1). All participants were European Caucasian and 
provided a medical history, physical examination and routine laboratory tests. Normal-weight patients reported 
no history of diabetes mellitus, high blood pressure, dyslipidemia or major body weight changes in the last 
3 months and were healthy overall. Exclusion criteria for study enrolment were pregnancy, alcohol or drug abuse 
and chronic prescriptions of other medical drugs different of antidiabetic medication.
Written informed consent to participate in the trial was obtained before the start of the study in agreement 
with the Declaration of Helsinki, and the study was performed following national and European Union guide-
lines. The protocol of this study was approved by the Clinica Universidad de Navarra Ethics Committee.
BMI was calculated as the weight in kg divided by the squared height in meters and was categorized using 
the following World Health Organization (WHO) criteria: normal/under-weight, BMI < 25 kg/m2; overweight, 
25 ≤ BMI < 30 kg/m2; and obese, BMI ≥ 30 kg/m2 1. Then, patients were classified considering overweight and 
obese patients in the same group, as obese (BMI > 25 kg/m2) and non-obese (BMI ≤ 25 kg/m2) to evaluate the 
effect of excess body weight.
The obese subcutaneous adipose tissue was obtained by biopsy from the periumbilical area using a 6-mm 
Bergstrom needle (Stile AB, Sweden) under local anesthesia (1% lidocaine). The non-obese subcutaneous adi-
pose tissue was collected from patients who underwent elective laparoscopic surgery for non-infectious and 
TargetID Gene name Function
Methylation levels (UNAV COHORT) Expression levels (GSE15524 GEO COHORT)
Obese Non-obese
Delta P-value
Obese Non-obese
Delta P-valueMean SD Mean SD Mean SD Mean SD
cg25932599 FGFRL1
Metabolism signaling and insulin 
processing35; cell proliferation and 
differentiation37
0.24 0.08 0.36 0.05 −0.11 0.002 2.80 2.93 0.70 0.49 2.10 0.067
cg25152348 NCAPH2 Senescence39 0.34 0.13 0.44 0.04 − 0.10 0.003 2.14 0.38 2.15 1.34 − 0.01 0.933
cg06936779 PIP5K1A
Involved in diverse cellular 
events through its product the 
phospholipid phophatidylinositol 
4.5-bi-sphosphate (PIP2)54
0.23 0.07 0.36 0.04 − 0.12 <0.001 0.20 0.14 0.26 0.19 − 0.06 0.683
cg22712983 PNKD Potentially involved in the mitochondrial function43 0.57 0.07 0.46 0.07 0.12 0.002 0.17 0.06 0.38 0.06 −0.21 0.024
cg02051077 PODXL
Proadhesive molecule involved 
in atherosclerosis55 and tumor 
growth56
0.27 0.07 0.38 0.02 −0.11 0.001 0.86 0.42 0.34 0.15 0.53 0.024
cg02874908 PTPRCAP Regulatory network of inflammation57 0.73 0.07 0.85 0.02 −0.14 <0.001 0.42 0.29 0.14 0.05 0.28 0.017
cg17858911 RSRC2 Tumor suppressor involved in cell proliferation58 0.25 0.07 0.36 0.08 − 0.12 0.002 12.49 6.56 13.05 4.71 − 0.57 0.940
cg0757622 SMAD3
Miscellaneous factor of 
adipogenesis. transdiferentiation 
and glucose homeostasis41
0.30 0.07 0.41 0.04 −0.11 <0.001 0.14 0.06 0.02 0.01 0.12 0.016
cg23713156 WDR45L No items found 0.23 0.08 0.34 0.04 −0.10 0.005 0.65 0.19 0.22 0.04 0.43 0.012
Table 2.  Relevant genes holding obesity-related differentially methylated CpGs (DMCpGs) and its 
association with gene expression. P value denotes statistical differences between obese and non-obese 
evaluated by Mann-Whitney U test.
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non-oncologic disease (see Supplementary Table S2) from the periumbilical area. Venous blood samples were 
drawn by venipunture after a 12-h overnight fast. The EDTA-plasma samples and leukocytes (all white blood 
Figure 5. Receiver operating characteristic (ROC) curves for the methylation levels of the obesity-related 
differentially methylated CpGs. The abilities to discriminate the obese from the non-obese samples of adipose 
tissue (a) and leukocytes (b).
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cells) were separated from whole blood by centrifugation (3500 rpm, 5 °C, 15 min), and were frozen immediately 
at − 80 °C in buffy-coat.
DNA preparation and bisulfite conversion. DNA from fresh-frozen (FF) tissue and blood samples was 
isolated using a standard phenol-chloroform/proteinase-k protocol according to the respective manufacturer’s 
instructions with slight modifications. The isolation of genomic DNA from subcutaneous adipose tissue was 
performed using the Qiagen DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA). Genomic DNA was isolated 
from leukocytes by using the MasturPure TM DNA purification kit (Epicentre Biotechnologies, Madison, WI, 
USA). The obtained DNA was treated with RNase A for 1 h at 45 °C. All DNA samples were quantified using 
the fluorometric method (Quan-iT PicoGreen DsDNA Assay, Life Technologies) and were assessed for purity 
using a NanoDrop (Thermo Scientific) with 260/280 and 260/230 ratio measurements. The integrity of the FF 
DNA was verified by electrophoresis in 1.3% agarose gel. FF DNA (600 ng) was processed using the EZ-96 DNA 
Methylation kit (Zymo Research Corp.) following the manufacturer’s recommendations for Infinium assays.
DNA methylation analysis. Infinium Human Methylation 450 BeadChip array. Microarray-based DNA 
methylation analysis was conducted with the Infinium Human Methylation 450 BeadChip (450k array). DNA 
quality checks, bisulfite modification, hybridization, data normalization, statistical filtering, and β value calcula-
tions were performed as described elsewhere52. High-quality DNA samples obtained from subcutaneous adipose 
tissue and leukocytes were selected for bisulfite conversion (Zymo Research; EZ-96 DNA Methylation™ Kit) and 
hybridization to the Infinium Human Methylation 450 BeadChips (Illumina) following the Illumina Infinium 
HD methylation protocol. The DNA concentration of the quality control sample standards was measured using 
the PicoGreen method (Invitrogen) coupled with assessments of DNA purity based on the A260/A280 ratio 
(ranging between 1.75 and 1.95) and the A260/A230 ratio (ranging between 2.00 and 2.20). Analysis with 1% aga-
rose gel electrophoresis permitted the exclusion of samples with possible DNA fragmentation or RNA contamina-
tion. The Infinium Human Methylation 450 BeadChip provides coverage of > 450,000 CpG sites targeting nearly 
all of the RefSeq genes (> 99%)52. The chips were designed to cover the coding and non-coding genes without bias 
against those lacking CpG islands. The design further aimed to cover not only promoter regulatory regions but 
also CpGs across gene regions to include the 5′ -untranslated regions (5′ UTRs), the first exons, the gene bodies 
and the 3′ -untranslated regions (3′ UTRs).
A total of 600 ng from the high-quality DNA samples was bisulfite converted. Whole-genome amplification 
and hybridization were then performed on the BeadChip and followed by single-base extension and analysis on 
a HiScan SQ module (Illumina) to assess the cytosine methylation states. The annotation of the CGIs used the 
following categorization: 1) shore, for each of the 2-kb sequences flanking a CGI; 2) shelf, for each of the 2-kb 
sequences next to a shore; and 3) open sea, for DNA not included in any of the previous sequences or in CGIs52. 
The transcription start site 200 and the transcription start site 1500 indicate the regions either 200 or 1500 bp from 
the transcription start site, respectively.
Gene expression assay. Gene expression levels of subcutaneous adipose tissue were obtained and ana-
lyzed from a previously published gene expression microarray dataset deposited at the Gene expression omnibus 
(GSE15524 GEO COHORT)24. Briefly, this study consisted in individualized analysis through expression profil-
ing of 20,000 probes in 28 tissue samples evaluated in subcutaneous and omental adipose tissue obtained during 
surgical intervention in non-obese and obese patients. Patient samples from men and women of varying body size 
(lean to severely obese) were collected at the time of operation in the fasting state including.
Statistical analyses. The methylation level of each cytosine was expressed as a β value that was calculated as 
the fluorescence intensity ratio of the methylated to the unmethylated alleles (Signal A and signal B are produced 
by two different bead types and reported in the same color) for infinium type I probes and (Signal A corresponds 
to the signal in the Red channel and signal B corresponds to the signal in the Green channel) for infinium type II 
probes. The β values ranged between 0 (unmethylated) and 1 (completely methylated) according to a combina-
tion of the Cy3 and Cy5 fluorescence intensities. Color balance adjustment and normalization were performed 
to normalize the samples between the two color channels using Genome Studio Illumina software (V2010.3). 
Genome Studio normalizes data using different internal controls that are present on the HumanMethylation 
450 BeadChip. This software also normalized data depending on internal background probes52. β values with 
detection p-values > 0.01 were considered to fall below the minimum intensity and threshold, and these CpGs 
(40,710) were consequently removed from further analysis. Approximately 96% of the CpG islands were covered, 
along with regions proximal to the CpG islands (“CpG shores”) and the more distal CpG shelves. Additionally, 
the probes that were localized to the sex chromosomes (11,234 CpGs form Chromosome X and 416 from chro-
mosome Y) and those CpGs that contain single nucleotide polymorphisms (SNPs) at the 10 bp 3′ end of the inter-
rogating probe (1,179 CpGs) were filtered out. Additionally 72 rs (controls SNPs probes) and 3,343 ch (non-CpG 
loci) probes were also removed. The final valid CpGs for the study were 428,882.To identify consistent patterns 
of differentially methylated CpG sites (DMCpGs) between the obese and normal-weight adipose tissue and leu-
kocyte samples, non-parametric Wilcoxon rank sum tests were performed. We performed Wilcoxon rank test for 
the analysis instead of using linear models or other methods able to adjust for confounding because of sample 
size. This test demonstrates quite robust results even for a small number of subjects. P values were adjusted for 
multiple comparisons using the false discovery rate (FDR) procedure of Benjamini and Hochberg. In this analy-
sis, a FDR below 5% was considered statistically significant. Additionally, we applied a threshold for the signifi-
cant sites based on the mean differences between groups with a minimum β value change of ± 0.05. Hierarchical 
cluster analysis of the significant CpGs was performed using the heatmap function. All of the mentioned statisti-
cal analyses were performed using R software (version 3.2.0). The global methylation level was compared between 
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obese and non-obese subjects by Wilcoxon rank test. The genomic distribution of the differentially methylated 
CpGs was compared with the distribution of the CpGs in all analyzed sites on the InfinumHumanMethylation 
450 BeadChip. P values were computed using the chi-square test to determine over- or under-representation of 
the CpGs.
To estimate the enrichment in biological processes, a hypergeometric test was performed on the biological 
processes defined by gene ontology (GO)52. This analysis detected the significant over-representation of GO terms 
in one of the sets (i.e., list of identified genes) with respect to the other for the entire genome. GO terms with an 
adjusted p-value < 0.05 were considered significant.
A Venn diagram was created by crossing the DMCpGs that were identified in the adipose tissue with those 
identified in the leukocytes. The list of common CpGs was further filtered out by probes which map to multiple 
genomic locations53. From the complete list of the DMCpGs that exhibited the same methylation direction in 
leukocytes and adipose tissue, those DMCpGS located in promoter regions and CpG islands and shores were 
selected. Among the DMCpGs met these criteria that DMCpGs exhibiting differences of similar magnitude in 
terms of the β-values in leukocytes and subcutaneous adipose tissue were identified as signature of obesity state 
and were further analized.
With the SPSS version 17.0 software (SPSS Inc., Chicago, IL) for Windows XP (Microsoft, Redmond, WA), the 
potential association between BMI and DNA methylation levels (β -values) was evaluated using the Pearson coef-
ficient test and a multivariate linear regression model was fitted to assess the association between the DNA meth-
ylation levels of the identified genes with BMI as a continuous variable adjusted for gender. Differences in DNA 
methylation levels and expression of the identified genes between groups were assessed by the non-parametric 
Mann Whitney U test. P ≤ 0.05 was considered statistically significant.
Additionally, the diagnostic efficiencies (percent correctly classified) of the candidate genes that were differ-
entially methylated were calculated as the agreement percentages using receiver operating characteristic (ROC) 
curve analyses. These results are often interpreted as negligible efficiency (< 20%), minimal efficiency (20–40%), 
moderate efficiency (41–60%), good efficiency (61–80%) and excellent efficiency (> 80%).
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